Overview

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Status:
Terminated

Trial end date:
2018-11-27

Target enrollment:

Participant gender:

Summary

To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE). To assess the primary bleeding events (PBE) of the rivaroxaban-based strategy compared to an antiplatelet-based strategy, following TAVR.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Collaborator:

Janssen Research & Development, LLC

Treatments:

Aspirin
Clopidogrel
Rivaroxaban
Vitamin K